FDA Approves First Drug for Friedreich’s Ataxia
Published on
The drug, omaveloxolone, is a once-a-day pill that will help improve neurological function and slow progression of the neurodegenerative disease.
Friedreich's Ataxia Program News and Updates
1 - 6 of 6
Friedreich’s Ataxia Center of Excellence at CHOP Awarded $1.275 Million to Advance Medical Research
Published on
The Friedreich’s Ataxia Center of Excellence at CHOP was awarded $1.275 million by the Friedreich’s Ataxia Research Alliance, Hamilton and Finneran families and the CureFA Foundation
In Pursuit of Cure for a Rare Degenerative Disease
Published on
A rare degenerative disease strikes during childhood. A multimillion-dollar gift is fueling CHOP scientists’ search for a cure.
Friedreich’s Ataxia: Taking Shots on Goal for a Rare Disease
Published on
Researchers rarely use the word "cure" when studying a rare disease with no approved therapies. At the Friedreich's Ataxia Center of Excellence, the word "cure" is now in the lexicon.
Amazing Grace
Published on
The new Friedreich’s Ataxia Center of Excellence gives hope and education to Grace Haupt and patients just like her.
$3.25 Million Gift Creates Friedreich’s Ataxia Center of Excellence
Published on
Donations from Friedreich’s Ataxia Research Alliance and the Hamilton and Finneran Families helps launch Penn Medicine/CHOP Center to improve research and care for Friedreich's Ataxia, a rare, degenerative disease.